A phase 3 study of apalutamide vs placebo in patients with metastatic hormone-sensitive prostate cancer receiving androgen deprivation therapy
K. Chi et al. Poster presented at ASCO Genitourinary Cancers Symposium; February 11-13, 2021. San Francisco, CA
Janssen-Cilag NV - CP-211813 - 17-feb-2021 – vu/er Luc Van Oevelen, Antwerpseweg 15-17, 2340 Beerse
Final analysis results from TITAN: